In a setback for Danish pharma giant Novo Nordisk and its blockbuster weight loss drugs containing semaglutide, the Delhi High Court Friday refused to grant an interim stay on a court order from last week that allowed Indian pharma company, Dr Reddy’s Laboratories (DRL), to manufacture and export the drug to countries where Novo Nordisk does not hold a patent over it.

The drug, belonging to the GLP-1 class of drugs, is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a patent dispute in India.

Novo Nordisk had appealed against a single judge’s order from December 2 which had refused to restrain DRL from manufacturing and exporting the drug. The court had drawn a prima facie conclusion that DRL has put up a credible challe

See Full Page